W
Wendy S. Stevens
Researcher at National Health Laboratory Service
Publications - 156
Citations - 11695
Wendy S. Stevens is an academic researcher from National Health Laboratory Service. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 44, co-authored 147 publications receiving 10184 citations. Previous affiliations of Wendy S. Stevens include University of the Witwatersrand.
Papers
More filters
Journal ArticleDOI
Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk
Jairam R. Lingappa,James P. Hughes,Richard S. Wang,Jared M. Baeten,Connie Celum,Glenda Gray,Wendy S. Stevens,Wendy S. Stevens,Deborah Donnell,Mary S. Campbell,Carey Farquhar,Myron Essex,James I. Mullins,Robert W. Coombs,Helen Rees,Lawrence Corey,Anna Wald,Hiv Transmission Study Team +17 more
TL;DR: This model is based on follow-up of 3381 HIV-1 serodiscordant couples over 5017 person-years encompassing 108 genetically-linked HIV- 1 transmission events and estimates that 90% of overall HIV-2 infections averted by a 0.74 copies/mL reduction could be achieved by targeting this reduction to the 58% of the cohort with plasma HIV-3 levels ≥4 log10 copies/ mL.
Journal ArticleDOI
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF
Gavin J. Churchyard,Gavin J. Churchyard,Wendy S. Stevens,Wendy S. Stevens,Lerole D Mametja,Kerrigan McCarthy,Violet N. Chihota,Mark P. Nicol,Mark P. Nicol,Linda Erasmus,Norbert Ndjeka,L Mvusi,Anna Vassall,Edina Sinanovic,Helen Cox,Christopher Dye,Alison D. Grant,Alison D. Grant,Katherine Fielding +18 more
TL;DR: Xpert did not reduce mortality at 6 months compared with sputum microscopy, and improving outcomes in drug-sensitive tuberculosis programmes might require not only better diagnostic tests but also better linkage to care.
Journal ArticleDOI
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?
TL;DR: The potential value of Xpert MTB/RIF as a point-of-care diagnostic for drug-sensitive and drug-resistant TB is discussed, and the potential indications for the assay in resource-limited, high-HIV burden settings are outlined.
Journal ArticleDOI
Effect of pretreatment HIV-1 drug resistance on immunological virological and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
Raph L. Hamers,Rob Schuurman,Kim C. E. Sigaloff,Carole L. Wallis,Cissy Kityo,Margaret Siwale,Kishor Mandaliya,Prudence Ive,Mariette E. Botes,Maureen Wellington,Akin Osibogun,Ferdinand W. N. M. Wit,Michèle van Vugt,Wendy S. Stevens,Tobias F. Rinke de Wit +14 more
TL;DR: Improved access to alternative combinations of antiretroviral drugs in sub-Saharan Africa is warranted and improved access to alternatives to pretreatment drug resistance is warranted.
Journal ArticleDOI
HIV-1 Viral Load Assays for Resource-Limited Settings
Susan A. Fiscus,Ben Cheng,Suzanne M. Crowe,Lisa M. Demeter,Cheryl Jennings,Veronica Miller,Richard Respess,Wendy S. Stevens +7 more
TL;DR: The authors discuss studies on the low-cost viral load assays that are currently available and their potential for use in resource-limited settings.